Noopur Raje, MD, Massachusetts General Hospital, Boston, MA, shares some insights into the role of immune checkpoint inhibitors (ICIs) in multiple myeloma and further comments on where these agents may fit in the future treatment landscape of this disease. This interview took place at the 20th International Myeloma Society (IMS) Annual Meeting, held in Athens, Greece.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.